GSK2636771: Clinical Trials

4 completed. 4 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4
Phase 2	2	Completed 2

Follow GSK2636771: new trials by email Literature Review of GSK2636771 trials Research Report on GSK2636771

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss GSK2636771, Pembrolizumab - Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma	Phase 1 / Phase 2	Completed	M.D. Anderson Cancer Center	28	2017-07-17	2026-08-27
PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma GSK2636771, Paclitaxel - Advanced Gastric Adenocarcinoma	Phase 1 / Phase 2	Completed	Yonsei University	42	2016-02-01	2025-01-24
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer GSK2636771, Enzalutamide - Neoplasms	Phase 1	Completed	GlaxoSmithKline	37	2014-11-13	2020-10-22
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency GSK2636771 - Cancer	Phase 1	Completed	GlaxoSmithKline	30	2011-11-10	2018-07-24

Conditions studied

Neoplasms (2)  ·  Melanoma (1)

Sponsors

GlaxoSmithKline (2)  ·  M.D. Anderson Cancer Center (1)  ·  Yonsei University (1)

Countries

United States (3)  ·  South Korea (2)  ·  United Kingdom (2)

Top investigators

Hussein Tawbi, MD, PHD (1)  ·  Sun Young Rha (1)

Results publications

PMID 34281912